PhaseV Raises $15 Million to Push the Boundaries of ML for Clinical Trial Optimization

Provided By PR Newswire

Last update: Oct 24, 2023

Clinical Trial Platform Uncovers Hidden Signals and Optimizes Next Steps for More Adaptive, Successful, and Efficient Clinical Trials

BOSTON, Oct. 24, 2023 /PRNewswire/ -- PhaseV a pioneer in causal machine learning (ML) technology that optimizes clinical trial design and analysis, announced today that it has raised $15 million in funding, led by Viola Ventures and Exor Ventures, including participation from LionBird and a group of prominent angel investors.